Abstract
Background/Introduction: Cardiotoxicity resulting in heart failure (HF) is a devastating complication of cancer treatment.
Purpose: To describe the characteristics and time to death of blood, lymphatic and breast cancer patients who died of heart failure (HF) comparing two groups, those who had an index HF hospital admission prior to death (HFA) and those who did not (NHFA).
Methods: Three health data sets for the period of 1996–2009 including Queensland Cancer Registry (QCR), Death Registry and Hospital Administration records for HF and chemotherapy admissions were linked for this study. Index HF admission must have occurred after cancer diagnosis.
Results: Within this cohort of 4894 patients, 734 were coded as HF related death (50.1% Female), 279 (38.0%) had at least one HF admission (41.9% Female) in the period of post cancer diagnosis. Median age of patients with HFA prior to death was 71 years (IQR 62-78) and 66 years (IQR 56-74) for NHFA. Patients with HFA received fewer chemotherapy cycles (median=4, IQR 2-9) than the NHFA patients (median=6, IQR 2- 12). Patients with an index HFA had 2.5 times increased risk of HF mortality than NHFA patients (HR 2.50 [95% CI, 2.14-2.92] after adjusting for covariates. 71% of the deceased cancer patients, who had an index HFA, died within one year of the index HF admission.
Conclusion: Once diagnosed with HF, almost three quarters of patients died within 12 months. Further research is underway by our team to explore the mechanisms underpinning these findings to help understand this high mortality.
Purpose: To describe the characteristics and time to death of blood, lymphatic and breast cancer patients who died of heart failure (HF) comparing two groups, those who had an index HF hospital admission prior to death (HFA) and those who did not (NHFA).
Methods: Three health data sets for the period of 1996–2009 including Queensland Cancer Registry (QCR), Death Registry and Hospital Administration records for HF and chemotherapy admissions were linked for this study. Index HF admission must have occurred after cancer diagnosis.
Results: Within this cohort of 4894 patients, 734 were coded as HF related death (50.1% Female), 279 (38.0%) had at least one HF admission (41.9% Female) in the period of post cancer diagnosis. Median age of patients with HFA prior to death was 71 years (IQR 62-78) and 66 years (IQR 56-74) for NHFA. Patients with HFA received fewer chemotherapy cycles (median=4, IQR 2-9) than the NHFA patients (median=6, IQR 2- 12). Patients with an index HFA had 2.5 times increased risk of HF mortality than NHFA patients (HR 2.50 [95% CI, 2.14-2.92] after adjusting for covariates. 71% of the deceased cancer patients, who had an index HFA, died within one year of the index HF admission.
Conclusion: Once diagnosed with HF, almost three quarters of patients died within 12 months. Further research is underway by our team to explore the mechanisms underpinning these findings to help understand this high mortality.
| Original language | English |
|---|---|
| Article number | 227 |
| Pages (from-to) | S207-S207 |
| Number of pages | 1 |
| Journal | Heart, Lung and Circulation |
| Volume | 24 |
| Issue number | Suppl_1 |
| DOIs | |
| Publication status | Published - Aug 2015 |
| Event | Cardiac Society of Australia and New Zealand Annual Scientific Meeting and the International Society for Heart Research Australasian Section Annual Scientific Meeting, 2015 - Melbourne, Australia Duration: 13 Aug 2015 → 16 Aug 2015 |
Keywords
- cancer patients
- heart failure
- cardiotoxicity
- mortality
